<DOC>
	<DOCNO>NCT01081964</DOCNO>
	<brief_summary>A double-blind , three-arm study , evaluate safety efficacy two dosing regimen zabofloxacin ( fluoroquinolone antibiotic ) community acquire pneumonia .</brief_summary>
	<brief_title>Safety Efficacy Study Oral Zabofloxacin Community Acquired Pneumonia</brief_title>
	<detailed_description>The study Phase 2 , global , prospective , multi-dose , double-blind , double-dummy , active-control , randomize , parallel-group , multicenter study oral zabofloxacin HCl ( 400mg ) versus oral levofloxacin ( 500mg ) treatment adult community-acquired pneumonia moderate severity .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<criteria>Male female &gt; /= 18 year old Documented fever ( oral &gt; 100°F ( 37.8°C ) , tympanic &gt; 101°F ( 38.1°C ) must document within time frame 24 hour prior first dose 24 hour first dose study drug Communityacquired pneumonia moderate severity ( define PSI Risk Class II III ) require administration antibiotic Dyspnea and/or tachypnea ( &gt; 20 breaths/minute ) Clinical diagnosis pneumonia , demonstrate follow sign symptom : 1. new increase cough 2. production purulent sputum change character sputum subject normally purulent sputum 3. auscultatory finding pulmonary examination rale and/or evidence pulmonary consolidation ( e.g. , bronchial breath sound , egophony , dullness percussion ) Females must surgically sterile ( e.g. , tubal ligation , hysterectomy ) , postmenopausal least 2 year , childbearing potential , must negative urine pregnancy test ( βhuman chorionic gonadotropin [ βhCG ] ) prior randomization study . Males females must agree intercourse use least two medically accept method birth control ( e.g. , hormonal contraceptive , intrauterine device , spermicide , condom ) study entry 60 day discontinuation study drug treatment Able give write informed consent manner approve Institutional Review Board Ethics Committee comply requirement study Subjects must NOT meet follow exclusion criterion : Received one dos systemic antibiotic last 2 week Diagnosed infection require systemic antibacterial therapy Require longterm ( &gt; 7 day ) antibiotic therapy Previous diagnose condition might mimic complicate course evaluation infectious disease process ( e.g. , septic shock , bronchiectasis , lung abcess empyema , aspiration pneumonia , active tuberculosis , pulmonary malignancy , cystic fibrosis , postobstructive pneumonia , etc . ) Hypothermia ( oral &lt; 96°F [ 35.6°C } , tympanic &lt; 97°F [ 35.9°C ] Hospitalization ( inpatient ) previous 60 day infection presumably acquire hospital Resident skilled nursing facility anytime previous 60 day infection presumably acquire skilled nursing facility Chronic infection Hepatitis B Any evidence , know carrier , Hepatitis C antibody Infection Clostridium difficile Immunocompromising illness , include know human immunodeficiency virus ( HIV ) positivity AIDS , organ ( bone marrow ) transplant recipient , hematological malignancy Psychotic disease , peripheral neuropathy , glucose6phosphate dehydrogenase deficiency ; uncontrolled poorly control diabetes . Diabetic subject stable stable course antihyperglycemic agent past 3 month permit trial . High exposure sunlight ultraviolet radiation Immunosuppressive therapy , include cancer chemotherapy chronic use corticosteroid ( i.e. , &gt; 20mg prednisone equivalent per day &gt; /= 14 day within last 6 month History renal hepatic disease define least one following : 1 . Calculated creatinine clearance &lt; 50 mL/min ( subject dialysis must exclude ) 2 . BUN &gt; /= 30 mg/dL 3 . ALT AST &gt; 3x ULN 4 . Total bilirubin &gt; 2x ULN 5 . Alkaline phosphatase &gt; 1.25x ULN History current malabsorption condition ( i.e. , short bowel syndrome , active Crohn 's disease , celiac disease , etc . ) Neutropenia define absolute neutrophil count &lt; 1000 cells/mm3 . Subjects neutrophil count low 500 cells/mm3 permit reduction document due acute infectious process Platelet count &lt; 75,000/mm3 . Subjects platelet count low 50,000/mm3 permit reduction historically stable Coagulation test &gt; 1.5x ULN ( PT , PTT , INR ) . Subjects anticoagulant value &gt; 1.5x ULN enrol , provide value historically stable within therapeutic range History alcohol drug abuse past 2 year History seizure currently receive antiseizure medication anytime past year , seizure past year History ventricular arrhythmia History QTc prolongation ( i.e. , &gt; 450msec ) observe QTc measurement screen &gt; 450msec , history additional risk factor Torsade de Pointe , heart failure , hypokalemia , familial history Long QT syndrome Require medication may prolong QTc interval Require medication affect absorption , include limited sucralfate cimetidine Require treatment theophylline , probenecid , vitamin K antagonist ( warfarin ; subject must stable dose warfarin within therapeutic range ) Pregnant , plan become pregnant , breast feeding Received investigational drug device within 30 day prior study entry Previously receive zabofloxacin clinical trial History allergy intolerability fluoroquinolones History fluoroquinolone tendinopathy Evidence immediately lifethreatening disease include , limited current impend respiratory failure , acute heart failure , shock , acute coronary syndrome , unstable arrhythmia , hypertensive emergency , acute hepatic failure , active gastrointestinal bleeding , profound metabolic abnormality ( e.g. , diabetic ketoacidosis ) , acute cerebrovascular event Current condition abnormality , opinion investigator , would compromise safety subject quality data Unable unwilling adhere sthe study specify procedure restriction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>pneumonia</keyword>
	<keyword>Community acquire pneumonia moderate severity</keyword>
</DOC>